JP2024510249A5 - - Google Patents

Info

Publication number
JP2024510249A5
JP2024510249A5 JP2023556900A JP2023556900A JP2024510249A5 JP 2024510249 A5 JP2024510249 A5 JP 2024510249A5 JP 2023556900 A JP2023556900 A JP 2023556900A JP 2023556900 A JP2023556900 A JP 2023556900A JP 2024510249 A5 JP2024510249 A5 JP 2024510249A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
group
membered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510249A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/020687 external-priority patent/WO2022197885A1/en
Publication of JP2024510249A publication Critical patent/JP2024510249A/ja
Publication of JP2024510249A5 publication Critical patent/JP2024510249A5/ja
Pending legal-status Critical Current

Links

JP2023556900A 2021-03-19 2022-03-17 神経疾患を治療するための組成物およびその方法 Pending JP2024510249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163546P 2021-03-19 2021-03-19
US63/163,546 2021-03-19
PCT/US2022/020687 WO2022197885A1 (en) 2021-03-19 2022-03-17 Compositions and methods for treating neurologic diseases

Publications (2)

Publication Number Publication Date
JP2024510249A JP2024510249A (ja) 2024-03-06
JP2024510249A5 true JP2024510249A5 (cg-RX-API-DMAC7.html) 2025-03-26

Family

ID=83320987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556900A Pending JP2024510249A (ja) 2021-03-19 2022-03-17 神経疾患を治療するための組成物およびその方法

Country Status (10)

Country Link
US (2) US20240165077A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024510249A (cg-RX-API-DMAC7.html)
KR (1) KR20230159546A (cg-RX-API-DMAC7.html)
CN (1) CN117355525A (cg-RX-API-DMAC7.html)
AU (1) AU2022239497A1 (cg-RX-API-DMAC7.html)
CA (1) CA3212092A1 (cg-RX-API-DMAC7.html)
IL (1) IL306063A (cg-RX-API-DMAC7.html)
MX (1) MX2023010831A (cg-RX-API-DMAC7.html)
WO (1) WO2022197885A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026064542A1 (en) * 2024-09-18 2026-03-26 Cognition Therapeutics, Inc. 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms
WO2026119142A1 (zh) * 2024-12-03 2026-06-11 浙江径科医药有限公司 一种氘代异吲哚啉化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US20200000822A1 (en) * 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
JP2022537581A (ja) * 2019-06-21 2022-08-26 クラリス コーポレーション Ppm1阻害剤およびその使用方法
CN110283082A (zh) * 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法

Similar Documents

Publication Publication Date Title
JP2023553414A5 (cg-RX-API-DMAC7.html)
JP7158382B2 (ja) C-kit阻害剤としてのアミノチアゾール化合物
JP2022501430A5 (cg-RX-API-DMAC7.html)
JP2023501253A5 (cg-RX-API-DMAC7.html)
JP2023513680A5 (cg-RX-API-DMAC7.html)
JP2022510925A5 (cg-RX-API-DMAC7.html)
JP2020033357A5 (cg-RX-API-DMAC7.html)
JP2023552610A5 (cg-RX-API-DMAC7.html)
JP2018507877A5 (cg-RX-API-DMAC7.html)
JP2010538076A5 (cg-RX-API-DMAC7.html)
CN103936690A (zh) 氨基二氢噻嗪衍生物
CA2632194A1 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2006033005A2 (en) Thrombopoietin receptor agonists
JP2015504062A (ja) 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]−ピペラジンの製造方法
JPWO2020017587A5 (cg-RX-API-DMAC7.html)
PT1533304E (pt) Derivado de amida
JP2017507122A5 (cg-RX-API-DMAC7.html)
JP2012530765A5 (cg-RX-API-DMAC7.html)
JP2025514386A5 (cg-RX-API-DMAC7.html)
JP2017534569A5 (cg-RX-API-DMAC7.html)
EP2780331A1 (en) Pharmaceutically active pyrazine derivatives
JP2009503060A (ja) N−フェニル−2−ピリミジン−アミン誘導体及びそれの調製のための工程
JP2022533939A5 (cg-RX-API-DMAC7.html)
JP2022534434A5 (cg-RX-API-DMAC7.html)
JP2025509965A5 (cg-RX-API-DMAC7.html)